Characterization of PIVKA-II Molecular Forms via Size Exclusion Chromatography and Hydrophobic Interaction Chromatography in HCC Patients.

IF 2.9 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY
Yoshiyuki Kitamura, Katsumi Aoyagi
{"title":"Characterization of PIVKA-II Molecular Forms via Size Exclusion Chromatography and Hydrophobic Interaction Chromatography in HCC Patients.","authors":"Yoshiyuki Kitamura, Katsumi Aoyagi","doi":"10.1002/jcla.70114","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Protein induced by the absence of vitamin K or antagonist-II (PIVKA-II) is an important serological biomarker for the diagnosis of hepatocellular carcinoma (HCC). The crucial epitope of PIVKA-II comprises a series of Glu residues located in the Glu-Gla domain. The other antibody required for the PIVKA-II sandwich immunoassay recognizes prothrombin fragments 1 and 2. However, the molecular diversity of these regions has not been well documented.</p><p><strong>Methods: </strong>PIVKA-II immuno-reactivities in blood taken from HCC patients were analyzed by size exclusion chromatography (SEC) and hydrophobic interaction chromatography (HIC). Obtained fractions were subsequently tested using MU-3 monoclonal antibody (mAb) and a polyclonal anti-prothrombin antibody (pAb). Immuno-reactivity in each fraction was analyzed by an inhibition assay using prothrombin fragments and by a sandwich immunoassay.</p><p><strong>Results: </strong>SEC analysis of three paired serum and plasma samples gave a single peak of PIVKA-II immuno-reactivity corresponding to the expected molecular mass. However, HIC analysis using three paired sets and 14 HCC specimens revealed immuno-reactivity present in two distinct peaks of either low (peak-L: an elution position of 300-500 mM ammonium sulfate) or high (peak-H: an elution position of 100-300 mM ammonium sulfate) hydrophobicity or both peaks together. Immuno-reactivity of peak-L was inhibited by human prothrombin fragment-1 and detected by mAbs that recognize prothrombin-1. Immuno-reactivity of peak-H was inhibited by human prothrombin fragment-2 and detected by mAbs for prothrombin-2.</p><p><strong>Conclusions: </strong>These results demonstrate PIVKA-II exhibits molecular diversity, suggesting its potential as a diagnostic tool. This finding will contribute to further understanding of HCC and improve diagnostic accuracy.</p>","PeriodicalId":15509,"journal":{"name":"Journal of Clinical Laboratory Analysis","volume":" ","pages":"e70114"},"PeriodicalIF":2.9000,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Laboratory Analysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jcla.70114","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Protein induced by the absence of vitamin K or antagonist-II (PIVKA-II) is an important serological biomarker for the diagnosis of hepatocellular carcinoma (HCC). The crucial epitope of PIVKA-II comprises a series of Glu residues located in the Glu-Gla domain. The other antibody required for the PIVKA-II sandwich immunoassay recognizes prothrombin fragments 1 and 2. However, the molecular diversity of these regions has not been well documented.

Methods: PIVKA-II immuno-reactivities in blood taken from HCC patients were analyzed by size exclusion chromatography (SEC) and hydrophobic interaction chromatography (HIC). Obtained fractions were subsequently tested using MU-3 monoclonal antibody (mAb) and a polyclonal anti-prothrombin antibody (pAb). Immuno-reactivity in each fraction was analyzed by an inhibition assay using prothrombin fragments and by a sandwich immunoassay.

Results: SEC analysis of three paired serum and plasma samples gave a single peak of PIVKA-II immuno-reactivity corresponding to the expected molecular mass. However, HIC analysis using three paired sets and 14 HCC specimens revealed immuno-reactivity present in two distinct peaks of either low (peak-L: an elution position of 300-500 mM ammonium sulfate) or high (peak-H: an elution position of 100-300 mM ammonium sulfate) hydrophobicity or both peaks together. Immuno-reactivity of peak-L was inhibited by human prothrombin fragment-1 and detected by mAbs that recognize prothrombin-1. Immuno-reactivity of peak-H was inhibited by human prothrombin fragment-2 and detected by mAbs for prothrombin-2.

Conclusions: These results demonstrate PIVKA-II exhibits molecular diversity, suggesting its potential as a diagnostic tool. This finding will contribute to further understanding of HCC and improve diagnostic accuracy.

肝细胞癌患者PIVKA-II分子形态的大小排斥色谱和疏水相互作用色谱表征。
背景:缺乏维生素K或拮抗剂ii (PIVKA-II)诱导的蛋白是诊断肝细胞癌(HCC)的重要血清学生物标志物。PIVKA-II的关键表位包括位于Glu- gla结构域的一系列Glu残基。PIVKA-II三明治免疫分析法所需的另一种抗体识别凝血酶原片段1和2。然而,这些区域的分子多样性尚未得到很好的记录。方法:采用大小排斥层析(SEC)和疏水相互作用层析(HIC)分析肝细胞癌患者血液中PIVKA-II的免疫反应性。随后用MU-3单克隆抗体(mAb)和抗凝血酶原抗体(pAb)检测所得组分。利用凝血酶原片段和夹心免疫分析法进行抑制试验,分析各组分的免疫反应性。结果:三个配对血清和血浆样本的SEC分析显示PIVKA-II免疫反应性单峰与预期分子质量相对应。然而,使用3组配对样本和14个HCC标本进行的HIC分析显示,免疫反应性存在于两个不同的峰,或低(峰l:洗脱位置为300-500 mM硫酸铵)或高(峰h:洗脱位置为100-300 mM硫酸铵)疏水性或两个峰一起。峰l的免疫反应性被人凝血酶原片段-1抑制,并通过识别凝血酶原-1的单克隆抗体检测。h峰的免疫反应性被人凝血酶原片段-2抑制,并被凝血酶原-2单克隆抗体检测。结论:这些结果表明PIVKA-II具有分子多样性,表明其作为诊断工具的潜力。这一发现将有助于进一步了解HCC并提高诊断准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Laboratory Analysis
Journal of Clinical Laboratory Analysis 医学-医学实验技术
CiteScore
5.60
自引率
7.40%
发文量
584
审稿时长
6-12 weeks
期刊介绍: Journal of Clinical Laboratory Analysis publishes original articles on newly developing modes of technology and laboratory assays, with emphasis on their application in current and future clinical laboratory testing. This includes reports from the following fields: immunochemistry and toxicology, hematology and hematopathology, immunopathology, molecular diagnostics, microbiology, genetic testing, immunohematology, and clinical chemistry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信